Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives

References

• de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am. Heart J. 127(3), 643–651 (1994).
   PubMed Web of Science ®Google Scholar
• Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 316(12), 701–706 (1987).
   PubMed Web of Science ®Google Scholar
• Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301(2), 61–68 (1979).
   PubMed Web of Science ®Google Scholar
• Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J. Am. Coll. Cardiol. 12(3), 616–623 (1988).
   PubMed Web of Science ®Google Scholar
• Gruentzig AR, King SB 3rd, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N. Engl. J. Med. 316(18), 1127–1132 (1987).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 77(2), 361–371 (1988).
   PubMed Web of Science ®Google Scholar
• Kimura T, Kaburagi S, Tamura T et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation 96(2), 475–483 (1997).
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94(6), 1247–1254 (1996).
   PubMed Web of Science ®Google Scholar
• Di Mario C, Gil R, Camenzind E et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am. J. Cardiol. 75(12), 772–777 (1995).
   PubMed Web of Science ®Google Scholar
• Luo H, Nishioka T, Eigler NL et al. Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. Arterioscler. Thromb. Vasc. Biol. 16(11), 1393–1398 (1996).
   PubMed Web of Science ®Google Scholar
• Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 49(3), 327–333 (1983).
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331(8), 489–495 (1994).
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331(8), 496–501 (1994).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 115(11), 1433–1439; discussion 1439 (2007).
   PubMed Web of Science ®Google Scholar
• Costa MA, Sabate M, van der Giessen WJ et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 100(8), 789–792 (1999).
   PubMed Web of Science ®Google Scholar
• Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104(17), 2007–2011 (2001).
   PubMed Web of Science ®Google Scholar
• Rensing BJ, Vos J, Smits PC et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur. Heart J. 22(22), 2125–2130 (2001).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol. 45(12), 2088–2092 (2005).
   PubMed Web of Science ®Google Scholar
• McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444), 1519–1521 (2004).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584–2591 (2006).
   PubMed Web of Science ®Google Scholar
• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52(14), 1134–1140 (2008).
   PubMed Web of Science ®Google Scholar
• Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46(2), 231–236 (2005).
   PubMed Web of Science ®Google Scholar
• Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27(2), 166–170 (2006).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371(9616), 899–907 (2008).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667), 897–910 (2009).
   PubMed Web of Science ®Google Scholar
• Okamura T, Garg S, Gutierrez-Chico JL et al. In-vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 5(8), 932–938 (2010).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58(15), 1578–1588 (2011).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Onuma Y, Ormiston JA et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122(22), 2301–2312 (2010).
   PubMed Web of Science ®Google Scholar
• Oberhauser JP, Hossainy S, Rapoza R. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention 5(Suppl. F), F15–F22 (2009).
   PubMedGoogle Scholar
• English J, Perrin D. Polyglycolide and polylactide. In: Handbook of Biodegradable Polymers. Wiseman DM, Kost J, Domb J (Eds). CRC Press, USA (1998).
   Google Scholar
• Onuma Y, Serruys PW, Perkins LE et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122(22), 2288–2300 (2010).
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64(1), 36–42 (1997).
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349(9), 847–858 (2003).
   PubMed Web of Science ®Google Scholar
• Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 3(3), 241–244 (2007).
   PubMed Web of Science ®Google Scholar
• Verheye S, Martinet W, Kockx MM et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J. Am. Coll. Cardiol. 49(6), 706–715 (2007).
   PubMed Web of Science ®Google Scholar
• Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 7(9), 1060–1061 (2012).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1(1), 58–65 (2005).
   PubMedGoogle Scholar
• Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2(3), 286–294 (2006).
   PubMedGoogle Scholar
• Bruining N, de Winter S, Roelandt JR et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc. Interv. 3(4), 449–456 (2010).
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia HM, Gonzalo N, Pawar R et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention 4(4), 443–448 (2009).
   PubMed Web of Science ®Google Scholar
• Schaar JA, De Korte CL, Mastik F et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation 108(21), 2636–2641 (2003).
   PubMed Web of Science ®Google Scholar
• Schaar JA, Regar E, Mastik F et al. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation 109(22), 2716–2719 (2004).
   PubMed Web of Science ®Google Scholar
• Maier W, Windecker S, Kung A et al. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 105(20), 2373–2377 (2002).
   PubMed Web of Science ®Google Scholar
• Gomez-Lara J, Brugaletta S, Diletti R et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur. Heart J. 32(3), 294–304 (2011).
   PubMed Web of Science ®Google Scholar
• Diletti R, Onuma Y, Farooq V et al. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J. Am. Coll. Cardiol. 58(3), 258–264 (2011).
   PubMed Web of Science ®Google Scholar
• Brugaletta S, Garcia-Garcia HM, Diletti R et al. Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. EuroIntervention 6(9), 1110–1116 (2011).
   PubMed Web of Science ®Google Scholar
• Brugaletta S, Gomez-Lara J, Serruys PW et al. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial. JACC Cardiovasc. Interv. 4(12), 1281–1289 (2011).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ. Cardiovasc. Interv. 4(5), 535–538 (2011).
   PubMed Web of Science ®Google Scholar
• Nishio S. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-L-lactic acid coronary stents. Presented at: EuroPCR. Paris, France, 25–28 May 2010.
   Google Scholar
• Davies G, Hamilton S, Hendrickson E, Levy R, Post F. The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients. Age Ageing 6(3), 156–162 (1977).
   PubMedGoogle Scholar
• Biamino G, Schmidt A, Scheinert D. Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS study. J. Endovasc. Ther. 12(Suppl.), 5 (2005).
   PubMedGoogle Scholar
• Schulze R. REVA Medical, Inc. Bioresorbable stent. Presented at: Cardiovascular Revascularization Therapies. Washington, DC, USA, 7–9 March 2007.
   Google Scholar
• Grube E. Bioabsorbable stent. The Boston Scientific and REVA technology. Presented at: EuroPCR 2009. Barcelona, Spain, 19–22 May 2009.
   Google Scholar
• Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention 5(Suppl. F), F58–F64 (2009).
   PubMedGoogle Scholar
• Lafont A, Durand E. A.R.T.: concept of a bioresorbable stent without drug elution. EuroIntervention 5(Suppl. F), F83–F87 (2009).
   PubMedGoogle Scholar
• Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369(9576), 1869–1875 (2007).
   PubMed Web of Science ®Google Scholar
• Barlis P, Tanigawa J, Di Mario C. Coronary bioabsorbable magnesium stent: 15-month intravascular ultrasound and optical coherence tomography findings. Eur. Heart J. 28(19), 2319 (2007).
   PubMed Web of Science ®Google Scholar
• Ghimire G, Spiro J, Kharbanda R et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention 4(4), 481–484 (2009).
   PubMed Web of Science ®Google Scholar
• Waksman R, Erbel R, Di Mario C et al. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc. Interv. 2(4), 312–320 (2009).
   PubMed Web of Science ®Google Scholar
• Leimgruber PP, Roubin GS, Hollman J et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 73(4), 710–717 (1986).
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Mehran R, Dangas G et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur. Heart J. 28(16), 1936–1945 (2007).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360(10), 961–972 (2009).
   PubMed Web of Science ®Google Scholar
• Di Mario C WG, Sianos G, Galassi AR et al. European Perspective in the Recanalization of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention 3, 30–43 (2007).
   PubMedGoogle Scholar
• Spuentrup E, Ruebben A, Mahnken A et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation 111(8), 1019–1026 (2005).
   PubMed Web of Science ®Google Scholar
• Bruining N, Tanimoto S, Otsuka M et al. Quantitative multi-modality imaging analysis of a bioabsorbable poly-l-lactic acid stent design in the acute phase: a comparison between 2- and 3D-QCA, QCU and QMSCT-CA. EuroIntervention 4(2), 285–291 (2008).
   PubMedGoogle Scholar
• Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur. Heart J. 33(1), 16–25 (2011).
   PubMedGoogle Scholar